Integrin Antagonists 27

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: Integrin Antagonists 27
• 英文别名: 3-[2-[(Z)-[1-[2-(4-methylanilino)-2-oxoethyl]-2,5-dioxoimidazolidin-4-ylidene]methyl]pyrrol-1-yl]benzoic acid
• 化学式: C₂₄H₂₀N₄O₅
• 分子量: 444.4
• InChiKey: BJCKKLXERBMNHP-MOSHPQCFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] COMPOSITIONS FOR CONTROLLING VASCULARIZATION IN OPHTHALMOLOGICAL AND DERMATOLOGICAL DISEASES<br/>[FR] COMPOSITIONS DESTINÉES À CONTRÔLER LA VASCULARISATION DANS LE CADRE DE MALADIES OPHTALMOLOGIQUES ET DERMATOLOGIQUES
  申请人：AVIENNE PHARMACEUTICALS GMBH

  公开号：WO2013057183A1

  公开（公告）日：2013-04-25

  A treatment method for controlling vascularization in a patient's eye or skin includes administering to the patient's eye or skin a pharmaceutical composition having formula (I) or a pharmaceutically acceptable salt, hydrate, enantiomer, diastereomer, racemate or mixtures of stereoisomers thereof. wherein the patient has a disease or disorder associated with vascularization in the eye or skin or wherein said patient is at risk for developing a disease or disorder associated with vascularization of the eye or skin.

  控制患者眼部或皮肤血管生成的治疗方法包括向患者眼部或皮肤施用具有化学式（I）或其药用可接受的盐、水合物、对映体、二对映体、外消旋体或其立体异构体混合物的药物组合物。其中患者患有与眼部或皮肤血管生成相关的疾病或紊乱，或者该患者有患上与眼部或皮肤血管生成相关的疾病或紊乱的风险。
• Methods and compositions for controlling vascularization in ophthalmological and dermatological diseases
  申请人：Jansen Burkhard

  公开号：US20130102645A1

  公开（公告）日：2013-04-25

  A method for controlling vascularization in a patient's eye or skin includes administering to the patient's eye or skin a pharmaceutical composition having or a pharmaceutically acceptable salt, hydrate, enantiomer, diastereomer, racemate or mixtures of stereoisomers thereof, wherein the patient has a disease or disorder associated with vascularization in the eye or skin or wherein said patient is at risk for developing a disease or disorder associated with vascularization of the eye or skin.

  控制患者眼部或皮肤血管生成的方法包括向患者眼部或皮肤施用含有药物组合物或其药用盐、水合物、对映体、二对映异构体、外消旋体或其立体异构体混合物的药物组合物，其中患者患有与眼部或皮肤血管生成相关的疾病或紊乱，或者该患者有患上与眼部或皮肤血管生成相关的疾病或紊乱的风险。
• Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases
  申请人：AVIENNE PHARMACEUTICALS GMBH

  公开号：US20140249191A1

  公开（公告）日：2014-09-04

  A treatment method for controlling vascularization in a patient's eye or skin includes administering to the patient's eye or skin a pharmaceutical composition having formula (I) or a pharmaceutically acceptable salt, hydrate, enantiomer, diastereomer, racemate or mixtures of stereoisomers thereof. wherein the patient has a disease or disorder associated with vascularization in the eye or skin or wherein said patient is at risk for developing a disease or disorder associated with vascularization of the eye or skin.

  一种用于控制患者眼部或皮肤血管生成的治疗方法，包括向患者的眼部或皮肤内给予具有公式（I）或其药学上可接受的盐、水合物、对映体、反异构体、外消旋体或其立体异构体混合物的药物组合物。其中，患者患有与眼部或皮肤血管生成有关的疾病或隐患，或者患者有患上与眼部或皮肤血管生成有关的疾病或隐患的风险。
• INTEGRIN-BINDING SMALL MOLECULES
  申请人：NEAMATI Nouri

  公开号：US20070155750A1

  公开（公告）日：2007-07-05

  The present invention relates to compositions containing integrin-binding small molecules. Also disclosed are methods of binding integrins to these small molecules and methods of identifying small molecules binding to integrins.
• US7928113B2
  申请人：——

  公开号：US7928113B2

  公开（公告）日：2011-04-19